Clinical trial · Observational
Radiomics in Pancreatic Cancer
Radiomics-based Detection and Outcome Prediction for Pancreatic Cancer
NCT05658679CI-TRIAL-00062814unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The images of patients with pancreatic cancer were collected and analyzed based on the methodes of radiomics
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- patients with pancreatic cancer
- description
- Patients with pancreatic tumors diagnosed clinically or pathologically
- label
- Participants without pancreatic cancer
- description
- Participants who judged the pancreas to be completely healthy through medical examination
Primary outcomes (1)
- measure
- 5-year survival rate
- timeFrame
- 1 week
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Gender unlimited, 18-80 years old; * Received abdominal imaging; * informed consent signed. Exclusion Criteria: * Pregnant / lactating women； * Contraindications of imaging examination。
References
Publications (1)
- DERIVEDFu N, Fu W, Chen H, Chai W, Qian X, Wang W, Jiang Y, Shen B. A deep-learning radiomics-based lymph node metastasis predictive model for pancreatic cancer: a diagnostic study. Int J Surg. 2023 Aug 1;109(8):2196-2203. doi: 10.1097/JS9.0000000000000469. PMID 37216230